Floatz logo

Mitoxantrone

Refractory Acute Leukemia

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversitySmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Refractory Acute Leukemia cohort.

Asset / SponsorPhaseRating
Omacetaxine
The First Affiliated Hospital of Soochow University
Phase 2CCC
5-azacytidine
The First Affiliated Hospital of Soochow University
Phase 2CCC
Quizartinib
M.D. Anderson Cancer Center
Phase 1/2CCC

Same molecule, other indications

Mitoxantrone is also rated in:

acute promyelocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
myeloid neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →